إعلان
إعلان

TELO

TELO logo

Telomir Pharmaceuticals, Inc. Common Stock

1.43
USD
برعاية
-0.04
-2.73%
٠٨ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

1.44

+0.01
+0.70%

تقارير أرباح TELO

النسبة الإيجابية المفاجئة

TELO تفوق 2 من 4 آخر التقديرات.

50%

التقرير التالي

بيانات التقرير القادم
٠٢ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.07
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+133.33%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-22.22%

Telomir Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On ١٠ نوفمبر ٢٠٢٥, TELO reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.07 USD, resulting in a 57.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an زيادة of 133.33% EPS, and زيادة of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Telomir Pharmaceuticals, Inc. Common Stock reported EPS of -$0.03, beating estimates by 57.98%, and revenue of $0.00, 0% as expectations.
The stock price moved up 3.65%, changed from $1.37 before the earnings release to $1.42 the day after.
The next earning report is scheduled for ٠٢ فبراير ٢٠٢٦.
Based on 3 المحللين, Telomir Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان